Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Multiple Myeloma 3Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Mesothelioma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoblastic Lymphadenopathy 1Gliosarcoma 1Glioma 1Glioblastoma 1Enteropathy-Associated T-Cell Lymphoma 1Brain Neoplasms 1

Interventions

Temozolomide 27Radiotherapy 21Radiation 11Radiotherapy, Conformal 10Surgical Procedures, Operative 9Magnetic Resonance Spectroscopy 8Carmustine 8Radiotherapy, Intensity-Modulated 7Erlotinib Hydrochloride 7temsirolimus 6Vorinostat 6Sirolimus 6Chemotherapy, Adjuvant 6Bevacizumab 6motexafin gadolinium 5cediranib 5Cilengitide 5Carboplatin 52,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 5tipifarnib 4Sorafenib 4Immunoglobulin G 4Disulfides 4Congresses as Topic 4Procarbazine 3O(6)-benzylguanine 3Nivolumab 3Neoadjuvant Therapy 3Lapatinib 3Ipilimumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Gliosarcoma × Automobiles × Clear all
NCT01454596 2019-08-21

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
18 enrolled 25 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡